Repatha evolocumab regulatory update

Amgen submitted an NDA in Japan for Repatha evolocumab to treat high cholesterol. A BLA for Repatha is under FDA review for the indication, with an Aug. 27 PDUFA date. Amgen submitted an MAA to EMA fo...